Acamprosate

Generic Name: Acamprosate

Brand Names: Campral

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₁NO_₄S

CAS Number: 77337-76-9

Unique Ingredient Identifier: N4K14YGM3J

Background: Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.

Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA). Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification, unlike naltrexone and disulfiram. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.

Indication: Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is also indicated for the maintenance of alcohol abstinence in patients who have undergone alcohol detoxification. This drug should be used with a psychosocial support program providing adequate support.

Associated Conditions: Alcohol Abstinence, Alcohol Dependency

Clinical Trials

Tempero Bio Secures $70M Series B to Advance Novel Addiction Treatment Through Phase 2 Trials

2 months ago

• Tempero Bio has raised $70 million in Series B financing to advance TMP-301, a novel mGluR5 negative allosteric modulator targeting the neurobiological basis of addiction, through Phase 2 clinical trials. • The company has already initiated a Phase 2 trial for alcohol use disorder and plans to begin cocaine use disorder studies within the next year, addressing conditions that affect millions of Americans with limited treatment options. • Industry veteran John Wagner, M.D., Ph.D., with over 20 years of drug development experience, will join Tempero Bio as Chief Medical Officer to oversee the clinical advancement of TMP-301.

Semaglutide Shows Promise in Reducing Alcohol Consumption and Cravings

6 months ago

• A new study reveals that semaglutide, known as Ozempic and Wegovy, significantly reduces alcohol cravings and consumption in individuals with alcohol use disorder. • Participants on semaglutide experienced fewer heavy drinking days and decreased alcohol intake during lab tests compared to those on a placebo, indicating potential therapeutic benefits. • The research suggests semaglutide's effects on alcohol cravings may surpass existing treatments, offering a promising avenue for addressing the unmet needs in alcohol use disorder. • Further studies are warranted to explore semaglutide's long-term efficacy, optimal dosages, and safety, particularly for individuals without obesity or diabetes.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy